For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,285,942 | 1,118,649 | 993,066 | 1,387,275.25* |
| General and administrative | 744,276 | 1,114,525 | 803,619 | 1,010,636* |
| Total operating expenses | 2,030,218 | 2,233,174 | 1,796,685 | 2,397,911.25 |
| Loss from operations | -2,030,218 | -2,233,174 | -1,796,685 | -2,397,911.25* |
| Interest income | 40,885 | 12,455 | 11,627 | 31,207* |
| Interest expense | - | - | - | 37.25* |
| Other income, net | 40,885 | 12,455 | 11,627 | 31,169.75* |
| Net loss | -1,989,333 | -2,220,719 | -1,785,058 | -2,366,741.5 |
| Basic EPS | -0.09 | -0.11 | -0.1 | -0.157 |
| Diluted EPS | -0.09 | -0.11 | -0.1 | -0.157 |
| Basic Average Shares | 21,609,488 | 19,850,080 | 17,082,425 | 15,116,548 |
| Diluted Average Shares | 21,609,488 | 19,850,080 | 17,082,425 | 15,116,548 |
NANOVIRICIDES, INC. (NNVC)
NANOVIRICIDES, INC. (NNVC)